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ABSTRACT Multiple enveloped RNA viruses of the family Paramyxoviridae and
Pneumoviridae, like measles virus (MeV), Nipah virus (NiV), canine distemper virus
(CDV), or respiratory syncytial virus (RSV), are of high clinical relevance. Each year a
huge number of lives are lost as a result of these viral infections. Worldwide, MeV
infection alone is responsible for over a hundred thousand deaths each year despite
available vaccine. Therefore, there is an urgent need for treatment options to coun-
teract these viral infections. The development of antiviral drugs in general stands as
a huge challenge due to the rapid emergence of viral escape mutants. Here, we dis-
close the discovery of a small-molecule antiviral, compound 1 (ZHAWOC9045), active
against several pneumo-/paramyxoviruses, including MeV, NiV, CDV, RSV, and parain-
fluenza virus type 5 (PIV-5). A series of mechanistic characterizations revealed that
compound 1 targets a host factor which is indispensable for viral genome replica-
tion. Drug resistance profiling against a paramyxovirus model (CDV) demonstrated
no detectable adaptation despite prolonged time of investigation, thereby mitigating
the rapid emergence of escape variants. Furthermore, a thorough structure-activity
relationship analysis of compound 1 led to the invention of 100-times-more potent-
derivatives, e.g., compound 2 (ZHAWOC21026). Collectively, we present in this study
an attractive host-directed pneumoviral/paramyxoviral replication inhibitor with
potential therapeutic application.
IMPORTANCE Measles virus, respiratory syncytial virus, canine distemper virus, and
Nipah virus are some of the clinically significant RNA viruses that threaten substan-
tial number of lives each year. Limited to no availability of treatment options for
these viral infections makes it arduous to handle the outbreaks. This highlights the
major importance of developing antivirals to fight not only ongoing infections but
also potential future epidemics. Most of the discovered antivirals, in clinical trials cur-
rently, are virus targeted, which consequently poses the challenge of rapid emer-
gence of escape variants. Here, we present compound 1 (ZHAWOC9045), discovered
to target viral replication in a host-dependent manner, thereby exhibiting broad-
spectrum activity against several members of the family Pneumo-/Paramyxoviridae.
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The inability of viruses to mutate against the inhibitor mitigated the critical issue of
generation of escape variants. Importantly, compound 1 was successfully optimized
to a highly potent variant, compound 2 (ZHAWOC21026), with a promising profile
for pharmacological intervention.
KEYWORDS paramyxovirus, pneumovirus, host-directed, replication, inhibitors, high
resistance barrier
While the urgent need for antivirals against ongoing infections is undeniable, oneof the lessons learned from the current COVID-19 pandemic is the need for
broad-spectrum antivirals that are readily deployable for the prevention of future out-
breaks (1). Paramyxoviridae and Pneumoviridae are among the families of single-
stranded, negative-sense RNA viruses that continue to pose a severe disease burden
globally. Moreover, a risk of a future pandemic mediated by a potential cross-species
transmission of widely distributed paramyxoviruses is very much a possibility (2).
Among the paramyxoviruses, measles virus (MeV) undoubtedly stands as one of the
important viruses as it accounts for the loss of over 100,000 human lives each year.
Despite the availability of an effective vaccine, the numbers of measles cases and
deaths are on the rise every year with a decade-high of measles case numbers in 2019
(3) owing to the drastic drop in vaccination (4). Canine distemper virus (CDV), another
important paramyxovirus, is also a highly contagious virus with an extensively wide
host range within the order Carnivora, namely, Canidae, Hyaenidae, Phocidae, Felidae,
Procyonidae, Mustelidae, Ursidae, and Viverridae. While a vaccine against CDV exists, its
efficacy depends on the targeted species, which in turn poses a challenge (5).
Respiratory syncytial virus (RSV), the most common cause of acute lower respiratory
infection (ALRI) in children younger than 5 years, was estimated to have killed 66,000
to 199,000 children in 2005, with 99% of these deaths occurring in developing coun-
tries (6). Despite the disease burden, various reasons (7) have hindered the develop-
ment of more effective, better-tolerated, and affordable antivirals against RSV. Nipah
virus (NiV), another deadly paramyxovirus, stands out as a potential pandemic threat
(8). Despite its high case-fatality rate, there is still no treatment available for either
humans or animals.
Therapeutic candidates with qualities such as being cost-effective, shelf-stable at
room temperature, compatible with oral administration, and safe for prophylactic use
in pediatric patients are deemed promising (9). Small therapeutic molecules, among
others, potentially meet these requirements. Against paramyxoviruses, no first-in-class
antiviral has been approved so far, despite several approaches reported earlier (10–14).
Among the best lead compounds, viral RNA-dependent RNA-polymerase (RdRp)-
directed inhibitors (e.g., ERDRP-0519) exhibited potent efficacy against MeV and CDV
both in vitro and in vivo (15–17). Recently, another potent antiparamyxovirus RdRp
compound (GHP-88309) was identified and exhibited attractive profiles in vivo (18).
Although these virus-directed antiviral compounds look promising, monotherapy
against such highly mutable RNA viruses still faces the key challenge of generation of
escape mutants. Interestingly, in 2011, a host-directed myxoviral inhibitor, namely,
JMN3-003, had been discovered that has a broad-spectrum activity against many dif-
ferent viruses (19). However, the further development of the compound remained
unreported. In the case of RSV, of many discovered antivirals, fusion (F)-protein inhibi-
tors such as presatovir in hematopoietic cell transplant (HCT) patients with upper respi-
ratory tract (URT) illness and ziresovir and JNJ-53718678 in hospitalized infants have
yielded encouraging results (7, 20–22). However, the possibility of frequent emergence
of F-protein amino acid mutations might reduce the drug susceptibility (7).
Among the novel approaches for antiviral drug development, host-directed thera-
pies have gained popularity over the last 2 decades. In contrast to the conventional
approach of targeting virus-encoded factors, development of antiviral drugs targeting
host factors (23) acts as an alternative therapeutic strategy toward mitigating the
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challenge of emergence of drug-resistant viruses. Moreover, given the fact that related
viruses may share common host cell pathways needed for their life cycle, host-directed
antiviral approaches hold the benefit of demonstrating potential broad-spectrum
efficacy.
In this study, we present the identification, characterization, and optimization of a
small antiviral molecule, compound 1 (ZHAWOC9045), discovered using a cell-based
bioassay we recently described combined with high-throughput screening (HTS) (24).
The compound exhibits broad-spectrum inhibitory activity against several members of
the Paramyxoviridae family (e.g., MeV, CDV, NiV, and PIV-5) and the Pneumoviridae fam-
ily (e.g., RSV). Through detailed structure-activity relationship (SAR) studies, the struc-
ture of compound 1 was successfully optimized to result in highly potent derivatives
characterized to have strong efficacy at very low concentrations of nanomolar range
against a panel of enveloped pathogenic RNA viruses.
RESULTS
Hit identification with potent antiviral activity. The high-throughput screening
(HTS) performed previously to identify novel entry inhibitors (24) also yielded several
compounds that were observed to enhance fusogenic activity (see Fig. S1A in the sup-
plemental material). To further understand the mechanisms by which those com-
pounds could potentially increase membrane fusion, around 20 compounds were
cherry-picked and counterscreened at the concentration of 10 mM using a recombi-
nant attenuated CDV strain, Onderstepoort (OP) expressing the mNeonGreen fluores-
cent protein (neon) as a reporter (OPneon). While no compound could be confirmed as
a significant fusion-inducer in the context of viral infection, to our surprise, compound
1 (F2205-0189 from Life Chemicals) presented a rather notable antiviral activity (Fig. 1A
and B). In order to determine the potency of the compound, the 50% inhibitory con-
centration (IC50) of compound 1 was measured by employing either the attenuated
OP-CDV strain (OPneon/nLucP) or the wild-type A75/17 (A75)-CDV strain (A75neon/nLucP)
(Fig. 1C and D). The activity of the compound was compared with the previously
described entry inhibitor compound 3 (3G) (Fig. 1A) in Vero cells expressing the canine
signaling lymphocyte activation molecule (cSLAM) receptor (Vero-cSLAM). Note that
both recombinant viruses expressed the mNeonGreen (neon) and the nanoluciferase
(nLucP) reporter proteins (24). Remarkably, compound 1 exhibited a potent inhibitory
activity, with IC50 values of about 0.45 mM and 0.70 mM for OP-CDV and wild-type A75/
17, respectively, compared to compound 3 with 8mM (Fig. 1C and D).
In order to measure the cytotoxic activity of the compound, cell viability in the
presence of compound 1 or 3 was investigated using the RealTime-Glo MT cell via-
bility assay. Compound 1 presented a 50% cytotoxic concentration (CC50) value of
about 50 mM (Fig. 1E). Compound 1 exhibited a specificity index (SI; CC50/IC50) of
;100, whereas compound 3 displayed an SI value of about ;16 (Table 1).
Additionally, we investigated the impact of compound 1 on the cell cycle progres-
sion. To this aim, Vero-cSLAM cells were treated with increasing concentrations of
the compound and the cell cycle was analyzed by flow cytometry (Fig. 1F). The
data revealed that the compound causes the cell cycle arrest at G1 stage. However,
the impact was statistically significant only at concentrations as high as 30 mM,
about 60 times higher than the IC50 value.
In order to rule out the possibility that reduction of the signal was due to an impact
on the reporter protein, the effect of the compound was assessed on progeny virus
production. As expected, reduction of the viral yield corresponded with the reduction
of the luminescence signal (Fig. 1G), which validated the antiviral activity of compound
1. To exclude that preexisting compound (employed for the experiments) might have
affected the subsequent viral titration, we also collected the lysates (cells plus superna-
tants) from noninfected but compound 1-treated cells and incubated them with virus.
Indeed, the preexisting compounds did not exhibit any impact on the outcome of the
viral titration analysis (Fig. 1G).
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Resynthesis of screening hit: compound 1 (ZHAWOC9045/F2205-0189). To rule
out false-positive results, the identity of the hit compound was confirmed by chemical
resynthesis (Fig. 2, route I). The reaction of the phenol building block with chloroacetic
acid resulted in the ether 4 with the carboxylic acid, which was coupled to 2-amino-
benzothiazole to form the amide in compound 1. This compound was found to be as
effective against CDV (Fig. S1B) as the purchased screening compound and was there-
fore employed for all the following experiments.
Compound 1 targets a postentry step of the viral life cycle. We next explored
the mode of action of compound 1. To investigate whether compound 1 acts on the F-
protein as compound 3 does, we determined the inhibitory activity against a com-
pound 3-escape mutant virus, namely, OPneon/F-V575C (25). Vero-cSLAM cells were
FIG 1 Discovery of a novel small-molecule antiviral. (A) Structure of compound 1 (F2205-0189), compound 3 (3G), ERDRP-0519
(16), and JMN3-003 (19). (B) Assessment of the compounds’ inhibitory impact on virus-induced syncytium formation. Microscopic
images of cells infected with OPneon in the presence of the compounds. Scale bars, 2,000 mm. Pictures were captured with a
Cytation 5 imaging multimode reader (BioTek). Note that due to automatic settings, discrepancy in background intensity
measurement is visible in the stitched images. (C) IC50 measurement of compounds against the attenuated OP-CDV strain. (D) IC50
measurement of compounds against the wild-type A75/17-CDV. (E) Measurement of the cytotoxic effect of the inhibitors. Ninety-
five percent confidence intervals are shown in parentheses. Relative luminescence values were normalized for values obtained in
the presence of DMSO control and represent means from three independent experiments. (F) Impact of compound 1 on cell
cycle progression of treated cells. Vero cells were incubated in the absence or presence of increasing concentration of compound
1 for 42 h and analyzed using flow cytometry. The values show the means 6 SD from three independent experiments. Dunnett’s
multiple-comparison test was applied after two-way analysis of variance (ANOVA) (*, P , 0.05). (G) Assessment of viral
proliferation after incubation with the compound. Vero cells expressing canine SLAM (cSLAM) were infected with wild-type A75/
17-CDV (A75neon/nLucP) at an MOI of 0.01 in the presence of increasing concentrations of the compound. After 30 h, infected cells
were frozen and thawed (twice), and viruses in the lysates were harvested and titrated in Vero-cSLAM cells.
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infected with the mutant virus in either the presence or absence of compound 1 or 3.
While OPneon/F-V575C successfully escaped compound 3, the virus remained, however,
highly sensitive to compound 1 (Fig. S2A). The absence of cross-resistance strongly
supported the idea that compound 1 inhibited viral infection through a different mo-
lecular mechanism. To further validate these findings, the impact of compound 1 on
the conformational stability of prefusion F-trimers was investigated. Indeed, it was
demonstrated that compound 3 increased prefusion F-protein’s stability, thereby
blocking the structural refolding necessary to fuse lipid membranes (26). The mem-
brane-anchored OP-CDV F-protein was submitted to a brief heat shock (10 min at 65°C;
a surrogate of F-activation) or kept at 37°C in the presence or absence of compounds 1
and 3. The conformation of F-protein was probed as reported previously (26), using a
prefusion-specific monoclonal antibody (anti-Pre) followed by flow cytometry analyses
to obtain semiquantitative data. While compound 3 indeed exhibited a strong stabiliz-
ing effect on prefusion F-trimers, compound 1 did not (Fig. S2B). Collectively, these
experiments further suggested that compound 1 did not interfere with the refolding
of the F-protein from the prefusion to the postfusion conformation.
Since the cell-to-cell fusion assay employed for HTS involved the cSLAM receptor,
we next investigated whether the activity of compound 1 relied on the presence of
cSLAM. To this aim, Vero cells stably expressing cSLAM or cNectin-4 (the CDV receptor
expressed in epithelial cells [27]) were infected with OPneon/nLucP in the presence of
increasing concentrations of compound 1 and relative luciferase activity was measured
in each of the cell lines. Note that OP-CDV employs a third unknown receptor (xR)
expressed in Vero cells. In all three infected cell lines, the activity of compound 1
remained equally efficient in terms of viral inhibition (Fig. 3A), which indicated that the
activity of compound 1 was cSLAM, cNectin-4, and xR independent.
To investigate whether the inhibitory activity of compound 1 was attributable to any
virucidal activities, virions (OPneon/nLucP) were incubated with either compound 3 or com-
pound 1 at inhibitory concentrations for 1 h at 4°C. The virus-compound mixtures were
then diluted 10-fold, thereby reaching noninhibitory concentrations. Hence, if the given
compound would efficiently interact with any components of the viral particle, the subse-
quent dilution step might not interfere with the inhibitory activity. Upon inoculation of the
diluted mixtures in Vero-cSLAM cells, the viral infectivity was assessed. While compound 3
still efficiently prevented viral infectivity even after the dilution step, compound 1 entirely
lost its inhibitory activity (Fig. 3B). These data strongly suggested that the mode of action
of compound 1 was not associated with virucidal activity.
TABLE 1 Comparison of SI values of initial hit 1 and optimized derivative 2 against several members of families Paramyxoviridae and
Pneumoviridaea
Family Virus Cell line Species
Compound 1 Compound 2
IC50 (mM) CC50 (mM) SI IC50 (mM) CC50 (mM) SI
Paramyxoviridae CDV (A75) Vero-cSLAM Monkey 0.70 52.0 74 0.0032 54.0 17,000
CDV (OP) Vero-cSLAM Monkey 0.45 52.0 120 0.0026 54.0 20,000
CDV (OP) Vero-cNectin-4 Monkey 0.43 43.0 100 ND ND ND
CDV (OP) Vero Monkey 0.40 46.0 120 0.0030 52.0 17,000
CDV (OP) MDCK Canine 30.00 99.0 3.3 0.0650 87.0 1,300
CDV (OP) P114 Canine 2.60 57.0 22 0.0190 65.0 3,400
CDV (OP) Bsr-T7 Hamster 7.30 50.0 6.8 0.0120 ND ND
MeV (Edm) Vero Monkey 0.25 46.0 180 ND ND ND
MeV (Edm) NCI-H358 Human 0.52 50.0 96 ND ND ND
MeV (ICB) NCI-H358 Human 0.37 50.0 140 ND ND ND
NiV PGSA745-EFNB2 Hamster ND ND ND 0.0800 80.0 1,000
PIV-5 Vero Monkey 7.20 46.0 6.4 0.0150 52.0 3,500
Pneumoviridae RSV HEp-2 Human 5.90 110.0 19 0.0310 51.0 1,700
Rhabdoviridae VSV Vero Monkey NA 46.0 NA NA 46.0 NA
aAbbreviations: NA, not applicable; ND, not determined.
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Next, a time-of-addition experiment was performed using OPneon/nLucP to investigate
which step of the viral life cycle may potentially be inhibited by compound 1. To this
end, Vero-cSLAM cells were treated with compound 1 at the time of infection or at dis-
tinct time points postinfection. In this set of experiments, two previously characterized
compounds (compound 3 and ERDRP-0519 [Fig. 1A]) targeting two distinct stages of
the viral life cycle (entry and replication, respectively) were added as controls.
Strikingly, while the profile of compound 1 inhibition differed from the one exerted by
compound 3, it acted like ERDRP-0519 (Fig. 3C), when compounds were added after 20
h of infection. Collectively, these findings provided good evidence that the antiviral ac-
tivity exerted by compound 1 was not mediated at the cell entry level but rather inter-
rupted the viral replication process.
Compound 1 inhibits the function of the RdRp complex. Since the viral RdRp
complex plays a pivotal role in replicating viral genomes, we tested whether com-
pound 1 could perturb the activity of the RdRp complex. In order to investigate this
notion, the bioactivity of compound 1 was determined employing a plasmid-based
minigenome system (mREP-OPneon/nLucP) in transfected Bsr-T7 cells. In this system, the
recorded luciferase activity corresponded to the RdRp complex activity and did not
rely on any other viral components. While, in the case of the entry inhibitor 3, the lucif-
erase activity remained similar to that for vehicle (dimethyl sulfoxide [DMSO])-treated
controls, 10mM compound 1 was sufficient to significantly inhibit the luciferase activity
(Fig. 3D). Again, the profile of compound 1-mediated viral inhibition appeared to be
very similar to the viral polymerase inhibitor ERDRP-0519. Moreover, consistent with
data obtained with CDV, inhibition of MeV polymerase activity was recorded, as
assessed by employing an MeV-based minigenome assay (Fig. S3). Taken together, this
set of experiments further confirmed that compound 1 targeted the replication stage
of CDV.
Compound 1 inhibits CDV in a host cell-dependent manner. It remained unclear
whether the compound directly targeted the RdRp complex or whether it exerted its
FIG 2 General synthesis routes for the optimization of compound 1. We used two main strategies to synthesize most of the new inhibitors.
In route I, we first built the ether moiety and coupled the aminothiazole moiety in the last step. This allows a convenient variation of the
thiazole moiety. In route II, we first coupled this thiazole moiety followed by the introduction of the phenol building block to vary the other
side of the scaffold. (a) NaOH in water at 100°C for 45 min (49). (b) N,N-Diisopropylethylamine (DIPEA) and N,N,N9,N9-tetramethyl-O-(7-
azabenzotriazol-1-yl)uronium hexafluorophosphate (HATU) in dimethylformamide (DMF) at 0°C to room temperature (RT) for 1 h. (c)
Triethylamine (TEA) in dichloromethane (DCM) at 0°C to RT for 1 h. (d) Cs2CO3 and NaI in DMF at 60°C overnight.
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FIG 3 Investigation of mode of action of compound 1. (A) IC50 measurement of compound 1 against the
attenuated OP-CDV strain in either Vero cells or Vero cells expressing SLAM (cSLAM) or Nectin4 (cN4) receptors.
(B) Investigation of virucidal effect of compound 1. As a positive control, compound 3 as a virucidal compound
was added. (C) OP-CDV time-of-addition studies. Compound 3 (entry inhibitor) and ERDRP-0519 (replication
inhibitor) were taken as references. Relative luminescence was measured after 48 h of initial infection. Relative
luminescence values were normalized for values obtained in the presence of DMSO control and represent
means 6 SD from three independent experiments. (D) Plasmid-based minigenome luciferase assay to
determine the bioactivity of CDV polymerase complex. Relative luminescence values were normalized for
values obtained in the presence of DMSO control and represent means 6 SD from three independent
experiments. Statistical significance of differences was determined using one-way ANOVA followed by
Dunnett’s multiple-comparison test (****, P , 0.0001; ns, not significant). (E) Antiviral activity of compound 1 is
host cell species specific. IC50 values of compound 1 were measured against the attenuated OP-CDV strain in
(Continued on next page)
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inhibitory function via targeting a host factor. In order to interrogate this idea, the bio-
activity of compound 1 was determined in cell lines of various species origin against
OPneon/nLucP. The IC50 values of the compounds were measured based on luciferase ac-
tivity. Interestingly, and despite being tested against the same virus, IC50 values of com-
pound 1 varied among different cell lines (Fig. 3E). We noted that the IC50 values
against OPneon/nLucP in Bsr-T7 cells were about 7 mM, which nicely corresponded with
the ;50% inhibition of polymerase activity recorded in the minigenome assay (gener-
ated in Bsr-T7 cells at 10 mM). Overall, the discrepancies in the inhibitory efficacy of
compound 1 in a host cell-dependent fashion indicated the possibility that the com-
pound might target a cellular factor promoting viral replication rather than the RdRp
directly.
In order to substantiate the possibility that compound 1 targeted the host cell fac-
tor, we opted for the direct visualization of the intracellular binding of compound 1 by
fluorescently labeling the compound using click chemistry. This technology involves a
highly specific and efficient chemical reaction of two binding moieties (alkyne and az-
ide [28]). To this end, compound 1 was tagged with alkyne (termed compound 1-alk
[20269], structure shown in Fig. 3G). The cellular localization of 1-alk was next deter-
mined by a click reaction with an azide-linked Alexa Fluor 488 molecule. Two irrelevant
alkyne-tagged compounds (20264 and 21320) were used as negative controls. Indeed,
a clear green fluorescent signal confirmed intracellular localization of 1-alk, whereas no
signal was detected for both control molecules (Fig. 3F). This observation was verified
in both Vero (monkey) and P114 (canine) cell lines. Of note, we also confirmed that the
addition of alkyne moiety on compound 1 did not compromise the inhibitory activity
of the compound (Table S5).
Compound 1 displays broad-spectrum antiviral activity. We next investigated
whether compound 1 displayed a broad-spectrum efficacy. To this end, the inhibitory
activity of compound 1 was determined against various related viruses: measles virus
(MeV) and parainfluenza virus type 5 (PIV-5) (both from the Paramyxoviridae family), re-
spiratory syncytial virus (RSV) (Pneumoviridae family), and vesicular stomatitis virus
(VSV) (Rhabdoviridae family). Susceptible cells were infected with MeV, PIV-5, RSV, and
VSV in the presence of increasing concentrations of compound 1 (Table 1). IC50 values
were determined either by recording luciferase activity (CDV, MeV, PIV-5, VSV) or by
plaque reduction assay (RSV). For MeV and CDV, the compound returned IC50 values of
in the range of 0.2 to 0.7 mM. The IC50 values for PIV-5 and RSV were about 7 and 6 mM,
respectively (Fig. 3H). Interestingly, compound 1 did not display any activity in the case
of VSV. Collectively, the recorded potent inhibitory activity of compound 1 against vari-
ous paramyxoviruses and pneumoviruses (but not rhabdoviruses) not only illustrated
the highly attractive broad-spectrum antiviral activity of the newly discovered com-
pound but also strengthened the notion that the compound 1 may target a host cellu-
lar factor necessary for promoting viral replication.
Compound 1 mitigates rapid emergence of viral resistance. Host-directed antivi-
ral strategy may not only provide molecules with broad-spectrum activity but may
additionally strongly reduce the chances of generation of drug-resistant viral variants
(23). Having demonstrated the former quality, we investigated the latter by performing
a stepwise viral growth adaptation in the presence of compound 1. In this set of
experiments, the previously described MeV polymerase-directed inhibitor, ERDRP-0519
(15), was included as control. The wild-type A75/17-CDV strain (A75neon) was employed
as the input virus for the adaptation. In order to let the virus adapt to the compound
FIG 3 Legend (Continued)
cell lines of different species origin. Ninety-five percent confidence intervals are shown in parentheses. (F)
Intracellular localization of alkyne-tagged compound 1 (1-alk) assessed through a click reaction using azide-
linked Alexa Fluor 488 in Vero and P114 cell lines. 20624 and 21320 were used as negative controls. Green
shows Alexa Fluor 488, and blue shows DAPI (nuclear staining). (G) Structure of three alkyne-tagged
compounds. (H) Compound 1 displays broad-spectrum activity. IC50 values of compound 1 were measured
against various viruses in corresponding cell lines. NA, not applicable. IC50 values of compound 1 were
measured against indicated viruses. Ninety-five percent confidence intervals are shown in parentheses.
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gradually, compound concentrations were doubled only once the virus-induced cyto-
pathic effect (CPE) became pronounced in the cell monolayer. Strikingly, while rapid re-
sistance to ERDRP-0519 emerged in approximately 20 to 25 days (tolerated dose at the
end of adaptation was $30 mM), compound 1 did not induce any detectable viral re-
sistance (in four separate replicates) until the end of the 83-day study (Fig. 4).
Collectively, these data not only supported the idea that compound 1 targeted a host
cellular factor but also illustrated that, in contrast to the virus-directed ERDRP-0519 in-
hibitor, our newly discovered molecule exhibits a high genetic resistance barrier.
Chemical optimization of compound 1. The variation of the molecule was divided
in three parts: the phenol component, the glycolic acid linker, and the thiazole compo-
nent. We diversified them to get better insights into the role of the fragments and
then combined the most promising building blocks. The glycolic acid linker allows a
convenient two-step synthesis with last-step derivatization to change the flanking phe-
nols and thiazoles.
Figure 2 illustrates the two generic synthetic routes toward compound 1 and deriv-
atives thereof. Either we formed the phenolic ether first, followed by an amide forma-
tion, or vice versa. The complete list of the final compounds with modified thiazole
moieties is shown in Fig. S5, scheme 1, and with modified phenol moieties in Fig. S5,
scheme 2. Most of the used phenol and 2-aminothiazole building blocks were commer-
cially available. Some phenol building blocks were synthesized starting with pyrogallol
(Fig. S5, scheme 3). We also synthesized specific 2-aminothiazole building blocks to es-
tablish our SAR (Fig. S5, scheme 4).
The glycolic acid linker was replaced with different functionalized linkers to look for
tolerated alternatives and to develop the SAR (Fig. S5, scheme 5). We synthesized
derivatives with alkyl groups at the a-position on the glycolic acid moiety and
extended linkers to explore possible attachment points. To find alternatives to the am-
ide bond in compound 1, we replaced it with ether, amine, ester, thioamide, and tria-
zole. The ether bond in compound 1 was replaced by an ester and an amide next to
the phenol moiety. We also synthesized derivatives with an additional ring system
between the a-position of the glycolic acid and the phenol fragment to investigate
whether the rigidified ligand has a higher activity. All IC50 values in this section were
measured using a quantitative viral inhibition assay based on Vero-cSLAM cells
infected with the recombinant CDV OPneon/nLuc. Luciferase activity was recorded 24 h
postinfection.
Structure-activity relationship (SAR) of the phenol moiety. The electron-rich
phenol moiety was exchanged with different phenols and anilines. The full list of the
compounds is shown in Table S1. Only fragments with larger substitutions in ortho or
fused five-ring systems in ortho to meta position with respect to the linking ether or
FIG 4 Compound 1 impedes the rapid emergence of viral mutants. Wild-type A75/17-CDV was
continuously adapted for 83 days in the presence of either ERDRP-0519 (virus directed) or compound
1 (host directed). Four independent adaptations were followed for compound 1 (green), whereas two
independent adaptations were followed for ERDRP-0519 (brown).
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amine group were tolerated. The active molecules pose an electron-rich aromatic sys-
tem like indoles or phenyls with at least another ether substituent. The indole frag-
ments favor the amine linkage (compound 5, IC50 = 0.73 mM, versus compound 6,
IC50 = 8.3 mM) while the 2,3-dihydrobenzofuran building block shows better inhibition
in combination with the ether linkage (compound 1, IC50 = 0.52 mM, versus compound
7, IC50 = 1.7 mM). Inhibitory activity was achieved with pyrogallol-based acetals. The
cyclopentyl acetal 8 and the isopropyl acetal 9 show the same activity as compound 1,
and an improvement was achieved with the heptyl-2-acetal derivative 10. This deriva-
tive was not further pursued due to its lipophilicity and the moderate stability of
acetals.
SAR of the benzothiazole moiety. The screening hit 1 has an unsubstituted benzo-
thiazole bound to the amide. Substitutions on the phenyl ring of the benzothiazole
were not well accepted (results shown in Table S2). Already, the introduction of a
methyl group in the position 4 or a fluorine in the position 6 leads to an activity
decrease. Larger substituents lead to an even larger loss of activity. In contrast to the
activity loss of the benzothiazoles, some alkyl-substituted thiazoles showed a signifi-
cant improvement (all results shown in Table S2). The unsubstituted thiazole 11 does
not have a strong inhibitory effect. A methyl group on the position 4 in compound 12
improves the IC50 to 2.2 mM and in position 5 in compound 13 improves it to 0.86 mM.
The thiazole 14 (IC50 = 0.13 mM) with two vicinal methyl groups and compound 15
results in improved inhibitory activity compared to compound 1. The highest inhibitory
activity in this series was found with the saturated ring systems in compounds 16
(0.084 mM) and 17 (0.056 mM), consequently. We also tested a wide variety of alkyl
amines and anilines, and none of them showed an activity at 100 mM (structures
shown in Fig. S5, scheme 6).
We replaced the benzothiazole with other aromatic heterocycles but could not
identify active alternatives (full list in Table S3). The benzothiophene derivative 18
showed no activity at 100 mM, and the benzoxazole 19 and benzimidazole 20 have an
IC50 higher than 40 mM. The nitrogen seems to play an important role either as an
interaction partner for binding to the target or for the electron density in the aromatic
system. The loss of the sulfur-to-oxygen interaction (as shown in Fig. 5) might explain
the high-affinity loss best. Benzimidazoles have a hydrogen bond donor. This would
also enable an intramolecular ON interaction like the OS contact (in Fig. 5) but
leads to an overall higher polarity. Only benzimidazoles with nonpolar substitutions on
the 1-position as in compound 21 remained active. This indicates a nonpolar binding
site in this orientation. Other aromatic five-membered rings show less or no activity
(Table S3).
A significant improvement of the IC50 was observed with extensions on the amide
FIG 5 Structure of the optimized inhibitor 2 (ZHAWOC21026) depicting the SAR conclusions. The
black arrow visualizes the possible C=OS interaction (50).
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nitrogen (Table S3). These tertiary amides were significantly more potent. A methyl
group in compound 22 boosts the activity 3-fold. The hydrogen bond-donating prop-
erty of the amide NH is therefore not necessary for the target binding. Larger substitu-
ents like the pentynyl in compound 23 or benzyl group in compound 24 are also well
tolerated. This confirms free space in this orientation and opens up possibilities to
attach functional moieties for binding studies. The activity improvements may also be
explained with better membrane permeability due to the reduced polarity of the com-
pound. The most active molecules resulted from the combination of the improved
thiazole fragments with amide nitrogen alkylations. The saturated fused thiazole deriv-
atives compounds 2 (ZHAWOC21026) and 25 (ZHAWOC21048) with an amide N-meth-
ylation have a much higher inhibitory activity than the according benzothiazole 22.
The lowest IC50 was fond with N-allyl in compounds 26 (ZHAWOC21027) and 27
(ZHAWOC20926) with 4.1 and 8.2 nM, respectively.
In summary, the thiazole moiety seems to be very important and small modifica-
tions lead to significant decreases in antiviral activity. The change from benzothiazole
to the cyclopentyl and cyclohexyl fused thiazoles and the extensions on the amide
nitrogen were beneficial for antiviral activity.
Linker moiety. We exchanged the glycolic acid linker with linkers of different
lengths and functional groups (Table S4). Employing the glycine-like linker in com-
pound 30 was well tolerated with a similar IC50 of 0.48 mM. The glycine linker in combi-
nation with an N-methylation and the optimized thiazole fragment in compound 31
was significantly more active. A methyl or butyl substituent on the a-position of the
glycolic acid in compounds 32 and 33 leads to an over-100-fold activity decrease.
Sterically, hindrance or clashes may explain this drop. The longer linker in compound 6
and linkers with ether 34, ester 35, triazole 36, thioamide 37, and amine 38 on the am-
ide position are not tolerated (full list in Table S5).
In Fig. 5, we summarize the overall results of our extensive derivatization process
leading to detailed SAR understanding.
Compound 2: a highly potent paramyxovirus and pneumovirus inhibitor.
Overall, our comprehensive SAR studies spotlighted three improved and highly potent
derivatives (compounds 2, 26, and 27), characterized by single-digit nanomolar activities.
Because those studies were based on infections performed with OP-CDV, it was of high im-
portance to determine whether or not the inhibitory activities of these compounds also
extended toward additional viruses. To that end, we selected compound 2 and tested its
inhibitory activity against A75/17-CDV, PIV-5, RSV, and NiV in corresponding cells.
Strikingly, similarly to OP-CDV, the inhibitory activity of the compound improved by about
100 times against all other tested members of the family Paramyxoviridae and
Pneumoviridae (Fig. 6A). Interestingly, CC50 values of compound 2 in all tested cell lines
remained similar, which in turn drastically improved the SI values of the compound
(Table 1). Moreover, the cell cycle proliferation was abrogated significantly only at concen-
trations as high as 1 mM (in Vero-cSLAM cells), a concentration about 200 times greater
than the inhibitory concentration (Fig. 6B). Note that this ratio was substantially improved
compared to the one calculated for our initial compound (of about 60 times for compound
1). Collectively, these findings highlighted the high potential of the newly designed com-
pounds as potent paramyxo- and pneumovirus inhibitors.
DISCUSSION
Every year, myriad infections caused by paramyxo- and pneumoviruses such as
MeV, CDV, and RSV bring a huge disease burden worldwide. Additionally, a highly
pathogenic virus like NiV is a particular concern as a potential source of human pan-
demics. While potent inhibitors indeed have been identified against members of the
Paramyxoviridae (15–18), the success of developing virus-directed antivirals in general
has been invariably challenged by the rapid generation of drug-resistant viruses (29–
34). A novel strategy of development of antivirals, by targeting rather a host factor, has
been widely explored (35–38). Many compounds identified in such a manner are in the
Host-Direct Paramyxovirus and Pneumovirus Inhibitors ®
November/December 2021 Volume 12 Issue 6 e02621-21 mbio.asm.org 11
preclinical stages of development, with a few compounds even approved by the FDA
(23, 39).
In this study, compound 1 was identified using an HTS performed earlier to discover
entry inhibitors against CDV (24). Interestingly, compound 1 clustered with small-mole-
cule compounds, potentially enhancing fusion activity. When investigated in the con-
text of quantitative cell-to-cell fusion assay, compound 1 was indeed confirmed to
enhance fusion activity, although membrane fusion increased exclusively at high con-
centrations (see Fig. S4 in the supplemental material). It is assumed that small mole-
cules at high concentrations may lead to aggregation effects or nonspecific binding.
We thus speculate that compound 1, at high concentrations, might have destabilized
the CDV prefusion F state and resulted in a moderate acceleration of fusion activity.
Alternatively, compound aggregates might have disturbed the cellular lipid mem-
branes (including the plasma membrane), which possibly resulted in accelerated virus-
induced fusogenicity. Importantly, the dose-response analysis, in the context of viral
infection, highlighted the fact that hit compound 1 strongly inhibited the viral replica-
tion at concentrations as low as 1 mM.
The compound 1 was discovered to act in a host-directed fashion. Host-based inter-
ventions inevitably offer advantages over conventional virus-directed antivirals, such
as a higher barrier to drug resistance (23) due to lower genetic variability of host
FIG 6 Generation of highly potent variants of compound 1. (A) IC50 values of one of the 3 best
variants, compound 2, were measured against different members of families Paramyxoviridae and
Pneumoviridae in corresponding cell lines. Ninety-five percent confidence intervals are shown in
parentheses. (B) Impact of compound 2 on cell cycle progression of treated cells. Vero cells were
incubated in the absence or presence of increasing concentrations of compound 2 for 42 h and
analyzed using flow cytometry. The values indicate the means 6 SD from three independent
experiments. Dunnett’s multiple-comparison test was applied after two-way ANOVA (*, P , 0.05).
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factors compared with the mutation-prone nature of viral components. Indeed, no re-
sistance occurred with compound 1 when adapted for the period of 83 days (Fig. 4).
While given experiments indicated that the compound targets a host factor, the com-
plete identification of the host factor targeted by this class, however, remains
unknown. Undoubtedly, an approach of targeting host factors for antiviral therapy
compared to conventional virus-directed agents may carry a burden of cytotoxicity
and undesirable drug-induced side effects. When tested in various cell lines, com-
pound 1 appeared to have very low cytotoxicity and only minor impact on the cell
cycle progression. Noteworthy is the possibility of minimizing a problem of side effects
by orienting the inhibition with precision. In this regard, the application of a host-
directed antiviral strategy appears to be more suitable for the inhibition of infections
by pathogens predominantly associated with severe acute disease, such as those medi-
ated by most members of the family Paramyxoviridae. Indeed, the treatment duration
would likely be limited, and therefore, possible drug-related side effects might be
reduced.
Often, related viruses use common pathways for their replication in the course of
their life cycle, and therefore, a host factor-directed molecule offers a benefit of broad
target range. Indeed, compound 1 can very efficiently inhibit members of the family
Paramyxoviridae and even extends to members of the family Pneumoviridae (Table 1),
but not the members of the family Rhabdoviridae. This also highlights the commonality
of host factor usage among the related families of viruses. Interestingly, the compound
1 was codiscovered and hence patented by a company named Retrovirox (40).
However, the company identified this compound against primate lentiviruses, which
are not the immediate relatives of paramyxo-/pneumoviruses. In the published patent,
the mode of action has been described to be via inhibition of virus-mediated downreg-
ulation of major histocompatibility complex class I (MHC-I) molecules. Lack of addi-
tional publications prevented any interpretations of their findings with regard to our
mechanistic studies. Overall, (i) the variability in IC50 values depending on the host cell
used, (ii) the direct intracellular localization of the compound in uninfected cells, (iii)
the pan-paramyxoviral/pneumoviral antiviral activity, and (iv) the lack of rapid emer-
gence of resistant viruses even upon prolonged incubation with the compound
strongly supported the notion that compound 1 acts in a host-directed fashion.
In an effort to improve inhibitory efficiency of compound 1, we initiated a SAR study
of this compound. To this aim, we synthesized over 100 compounds and tested them
in the virus inhibition assay to develop a detailed understanding of the SAR. The set of
highly active compounds is quite narrow, and most parts of the hit molecule barely tol-
erate any modifications. By modifying the benzothiazole fragment and alkylations of
the amide nitrogen, we eventually invented very interesting single-digit nanomolar
inhibitors. Fortunately, the cytotoxicity (around 50 mM, depending on cell lines) was
not changed by these modifications, and the selectivity index consequently increased
to remarkable values (SI of 1,000 to 18,000) depending on the virus or cell line tested.
Altogether, we present a novel, host-directed small-molecule antiviral class (e.g.,
compound 2) with very high potency but low cytotoxicity. The compound inhibits sig-
nificant members of the families Paramyxoviridae and Pneumoviridae, including MeV,
CDV, NiV, PIV-5, and RSV. This class of compounds inhibits the replication via the RdRp
complex but, however in a host-directed manner, which in turn prohibits the emer-
gence of resistant mutants. Further exploration of the compound’s efficacy in vivo as
well as explicit identification of the host target might present these compounds as
promising candidates for therapeutic usage in the future.
MATERIALS ANDMETHODS
Cell culture and transfection. Vero cells (ATCC CCL1-81), Vero cells stably expressing canine SLAM
(Vero-cSLAM, kindly provided by Yusuke Yanagi, Kyushu University, Fukuoka, Japan), Vero-cSLAM-Green
Fluorescent Protein (GFP)/LgBiT, Vero-Fs-sH-Red Fluorescent Protein (RFP)/HiBiT, HEp-2 cells (ATCC, CCL-
23) baby hamster kidney cells stably expressing T7 polymerase (Bsr-T7/5) (41), and canine mammary
anaplastic cancer P114 (kindly provided by Elpetra Timmermans-Sprang, University of Utrecht, Utrecht,
Netherlands) (42) were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Invitrogen,
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Carlsbad, CA, USA) containing 10% fetal calf serum (FCS; BioSwissTech, Schaffhausen, Switzerland) and
penicillin-streptomycin (pen/strep) at 37°C and 5% CO2 (excluding Vero-Fs-sH-RFP/HiBiT cells, which
were cultured in the presence of 10 mM asunaprevir). All the transfections were done using Trans-It rea-
gent according to the manufacturer’s instruction (Mirus). Stable transfection of Vero-cSLAM-Green
Fluorescent Protein (GFP)/LgBiT and Vero-Fs-sH-Red Fluorescent Protein (RFP)/HiBiT has been described
previously (24).
Measles virus (MeV) rescue. The recombinant MeV Moraten vaccinal strain, expressing firefly lucif-
erase, was generated using pB(1)Mor-Luc plasmid, produced by introducing the firefly luciferase gene
sequence into a new transcription unit located between the P and M genes in the pB(1)MVvac2 plas-
mid, kindly provided by Roberto Cattaneo (Mayo Clinic, USA). The recombinant MeV IC323 strain,
expressing firefly luciferase, was generated by engineering pB(1)IC323-EGFP plasmid, kindly provided
by Yusuke Yanagi (Kyushu University, Japan). Briefly, the enhanced GFP (EGFP) gene was excised and
the firefly luciferase gene sequence was introduced into a new transcription unit located between the H
and L genes. Recombinant Moraten and IC323-luciferase were rescued in 293-3-46 cells as previously
described (43). Viral strains were produced and titrated on Vero/hSlam cells.
Parainfluenza virus type 5 (PIV-5) rescue. A plasmid containing the full-length genome of PIV-5
strain W3A (termed pBH276; kindly provided by Biao He, Department of Infectious Diseases, University
of Georgia College of Veterinary Medicine, USA) was modified in two steps. First, a T7 promoter, an
Hhrbz sequence, the PIV-5 W3A leader sequence, and an mNeonGreen gene were inserted to the N ter-
minus of the N gene together with a P2A motif (commercially constructed in one fragment; Eurofins
Genomics Germany GmbH) for translational separation. Then, the nLucP gene (nanoluciferase gene
fused to the “pest” degradation motif; Promega) was cloned as an additional transcription unit between
the P and M genes. The obtained plasmid was designated PIV-5neon/nLucP. Recombinant PIV-5neon/nLucP
was rescued in Vero cells as previously described (24).
Virus inhibition assay. OPneon/nLucP (unpublished data), wild-type CDV strain (A75/17neon/nLucP) (44),
MeV-Edm, MeV-ICB (mentioned above), RSV-GFP (45), rNiV-EGFP (46), and PIV-5neon/nLucP (mentioned
above) have been rescued as described previously. Desired inhibitors, dissolved in DMSO, were added in
a 96-well plate (Greiner Bio-One) starting at 100 nM with increasing concentration of half a log up to
100 mM. Desired virus was then added to the plates at a multiplicity of infection (MOI) of 0.04 (OPneon/nLucP,
A75/17neon/nLucP, MeV-Edm, MeV-ICB, RSV, rNiV-EGFP) or 1 (PIV-5) and incubated at 4°C for 1 h. Mixtures
were then added to Vero-cSLAM cells (OPneon/nLucP, A75/17neon/nLucP, MeV-Edm, MeV-ICB, RSV, rNiV-EGFP) or
Vero cells (PIV-5) preseeded in a separate 96-well plate and incubated at 37°C for 24 h. The luminescence
was measured using the Nano-Glo live cell assay system (Promega) and a multiplate reader (Cytation 5;
BioTek, Winooski, VT, USA).
For RSV, due to the lack of luciferase reporter, plaques were counted. In order to do that, after 48 h
of infection, the cells were fixed and incubated with a biotinylated anti-RSV antibody (Bio-Rad) for 1 h,
followed by 30 min of incubation with ExtrAvidin peroxidase (Sigma) and staining with the 3,39-diamino-
benzidine substrate (Sigma). The average plaque count of four replicates of RSV-GFP (originally gener-
ated by Mark Peeples, Nationwide Children’s Hospital, Columbus, OH, USA [47])-infected HEp-2 cells at
1,000 PFU was taken as 0% inhibition.
Nipah virus was amplified and titrated in Vero E6 cells. PGSA745-EFNB2 cells (kindly provided by B.
Lee) were cultured in DMEM–F-12 supplemented with nonessential amino acids (NEAA) and were
seeded in 96-well plates. The following day, subconfluent cells were infected with 100 PFU of rNiV-EGFP.
After 1 h, cells were treated with antiviral compound in order to obtain expected final concentrations.
Controls were treated with a corresponding amount of vehicle (i.e., DMSO). After 24 or 48 h, RNA was
extracted from supernatant fluids and reverse transcribed. Obtained cDNA was used to quantify NiV N
(using historical primers; For, GGCAGGATTCTTCGCAACCATC; Rev, GGCTCTTGGGCCAATTTCTCTG) using
Platinum SYBR green qPCR SuperMix-UDG on a StepOnePlus real-time PCR system. Results were
obtained from 3 separate experiments.
MeV and NiV infections were carried out at the CIRI in a biosafety level 2 (BSL2) laboratory (Lyon)
and at the INSERM Jean Mérieux BSL4 laboratory in Lyon, France.
Cell viability was determined using either the MT cell viability kit (RealTime-Glo MT cell viability
assay; Promega) or alamarBlue. After the measurement, all statistical analysis was carried out using the
GraphPad Prism 8 package. IC50 and CC50 values were calculated from dose-response data sets through
4-parameter variable slope regression modeling; values are expressed with 95% confidence intervals
(CIs).
Virucidal effect. OPneon/nLucP (MOI of 4) was added in a plate containing or not each compound and
incubated for 60 min at 4°C. Afterward, the virus and compound mixture was diluted to a noninhibitory
drug concentration and added to a monolayer of Vero-cSLAM cells. After 24 h, luminescence was meas-
ured using the Nano-Glo live cell assay system (Promega).
Time-of-addition assay. Vero-cSLAM cells (96-well plate format) were infected with OPneon/nLucP at
an MOI of 0.04, in the presence of compound 3G (final concentration, 30mM), ERDRP-0519 (final concen-
tration, 10 mM), or ZHAWO9045 (final concentration 10 mM) added at the indicated time points. Control
cells were infected in the presence of equal amounts of DMSO. At 48 h postinfection, luminescence was
measured using the Nano-Glo live cell assay system (Promega).
Minireplicon transient expression assay. A cDNA-based OP-CDV (AF305419.1) minigenome was
synthetically synthesized (referred to as mREPneon/nLucP). Briefly, the minigenome consists of the following
sequence arrangements (from 59 to 39): T7 promoter, hammerhead (HH) ribozyme, leader, gene tran-
scription start, gene expression cassette (expressing both the mNeonGreen and nLuc reporter proteins
separated by a P2A sequence), gene transcription stop, trailer, T7 terminator, and the hepatitis delta
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ribozyme (HDV) sequence. In parallel, the OP-CDV sequence of the N, P, and L genes was cloned into the
T7-driven pTM expression vector. Note that (i) the C protein was knocked out from the pTM-P vector
(pTM-PCko) and (ii) the highly conserved glutamic acid at position 13 of the L protein had to be repaired
(L-V13E) to recover functionality. Finally, for detection purposes, the L protein was additionally tagged
with the hemagglutinin (HA) sequence at the N-terminal region (HA-L-V13E [unpublished data]). For the
CDV-based replication assays, Bsr-T7/5 cells were transfected with plasmid DNAs encoding CDV-OP-min-
igenome mREPneon/nLucP (0.8 mg), pTM CDV(OP)-N (0.3 mg), or pTM CDV(OP)-P/Cko (0.3 mg) and pTM CDV
(OP)-HA-L-V13E (0.1 mg) (unpublished data) in the presence of compounds. After 48 h of transfection,
the luminescence was measured using the Nano-Glo live cell assay system (Promega) and a multiplate
reader (Cytation 5; BioTek, Winooski, VT, USA). For MeV, the minireplicon transfection was performed as
described previously (48). As a negative control, compound 3 (entry inhibitor, 50 mM) and, as a positive
control, replication inhibitor (ERDRP-0519, 10 mM) were taken.
Click chemistry. Cells were seeded in a 24-well plate containing glass coverslips. Alkyne-tagged
compounds were added at the concentration of 2 mM and incubated at 37°C for 3 h. Afterward, cells
were washed, fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.2% Triton X-100 for
5 min, and blocked with 2% bovine serum albumin for 15 min. The click reaction was then performed
with the Click-iT cell reaction buffer kit (Invitrogen) according to the manufacturer’s instructions for 1 h.
The cells were washed, stained with 49,6-diamidino-2-phenylindole (DAPI), and analyzed by confocal mi-
croscopy (Olympus, Japan).
Virus adaptation. Vero-SLAM cells were infected with A75/17-CDV (A75green) at an MOI of 0.01
and incubated in the presence of gradually increasing concentration of ZHAWOC9045 starting at
0.5 mM. Simultaneously, the virus polymerase inhibitor ERDRP-0519 was examined in parallel. As
soon as extensive cell-to-cell fusion was visualized, cell-associated viral particles were extracted via
freeze-thaw cycles, diluted 10-fold, and inoculated in a fresh cell monolayer in the presence of com-
pound at unchanged or doubled concentrations. When cultures became overconfluent, cells were
reseeded for continued incubation in the presence of the same compound concentration as before.
Cultures treated with the highest compound concentrations in which virus-induced cytopathicity
became detectable were used for further adaptation. The adaptation was halted after 83 days of
continued incubation or, in the case of ERDRP-0519, when virus-induced cytopathicity was readily
detectable in the presence of 30 mM compound in accordance with previous results.
Synthetic chemistry. All final compounds were obtained with.95% purity.
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